Free Trial

TC Biopharm (TCBP) Stock Price, News & Analysis

0.00 (0.00%)
(As of 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
170,349 shs
Average Volume
3.52 million shs
Market Capitalization
$3.71 million
P/E Ratio
Dividend Yield
Price Target
TCBP stock logo

About TC Biopharm Stock (NASDAQ:TCBP)

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

TCBP Stock Price History

TCBP Stock News Headlines

Why Is TC Biopharm (TCBP) Stock Up 51% Today?
Why Is TC Biopharm (TCBP) Stock Up 78% Today?
TCBP Adjourns General Meeting Until a Later Date
TCBP Announces Exercise of Series D Warrants For Cash
/C O R R E C T I O N -- TC BioPharm/
See More Headlines
Receive TCBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TC Biopharm and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded


Pretax Margin


Sales & Book Value

Annual Sales
$4.76 million
Book Value
$0.43 per share


Free Float
Market Cap
$3.71 million
Not Optionable
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Bryan L. Kobel (Age 45)
    CEO & Director
  • Mr. Martin E. Thorp (Age 72)
    CFO & Director
  • Mr. Christopher Camarra
    Executive Vice President of Communications
  • Dr. Lauren Bor Ph.D.
    Head of Commercial Development Division

TCBP Stock Analysis - Frequently Asked Questions

How have TCBP shares performed in 2024?

TC Biopharm's stock was trading at $3.17 on January 1st, 2024. Since then, TCBP stock has decreased by 63.4% and is now trading at $1.16.
View the best growth stocks for 2024 here

When did TC Biopharm's stock split?

TC Biopharm shares reverse split before market open on Friday, December 15th 2023. The 1-20 reverse split was announced on Friday, December 15th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did TC Biopharm IPO?

TC Biopharm (TCBP) raised $17 million in an initial public offering (IPO) on Friday, February 11th 2022. The company issued 4,100,000 shares at a price of $4.25 per share. EF Hutton acted as the underwriter for the IPO.

How do I buy shares of TC Biopharm?

Shares of TCBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TCBP) was last updated on 5/22/2024 by Staff

From Our Partners